Inicure lead compound characterised as a specific agonist for FPR1, which displays a biased signalling profile that leads to a functional selective activating of the human neutrophils class (https://doi.org/10.1002/JLB.2HI0520-317R).
Functional selective FPR1 signaling in favor of an activationof the neutrophil superoxide generating NOX2 complex
AMR Conference Basel – 2026
Inicure particppated in the AMR conference i Basel meeting research collaborators, service providers and potential future commercial partners
INCATE – Network and Support
Inicure has been awarded support from the INCATE network (Incubator for Antibacterial Therapies in Europe). Access to advice and
Seal of Excellence – EIC – Transition proposal iCURE
The EIC-Transition proposal — iCURE “Novel small molecule FPR1 agonists for treating antibiotic-resistant and chronic bacterial infections” coordinated